Iron supplements concomitant with HIF-PHIs in the treatment of CKD anemia
Anemia is a common and important complication in patients with chronic kidney disease (CKD). Accordingly, the current treatment is based on erythropoiesis stimulating agents (ESAs) and iron. Hypoxia-inducible factor (HIF) prolyl hydroxylase domain (PHD) inhibitors (HIF-PHIs) have been developed to t...
Main Authors: | Xue Wang, Cuiting Wei, Delong Zhao, Xuefeng Sun, Fengge Zhu, Yan Mei, Qian Ma, Guangyan Cai, Xiangmei Chen, Ping Li |
---|---|
Format: | Article |
Language: | English |
Published: |
Karger Publishers
2023-08-01
|
Series: | Kidney Diseases |
Online Access: | https://beta.karger.com/Article/FullText/533304 |
Similar Items
-
PERCEPTION OF THE INCREASED RISK OF PHIS
by: Jana HANDRIKOVÁ, et al.
Published: (2021-06-01) -
CORRECTION OF IRON DEFICIENCY IN CKD V HD PATIENTS WITH ANEMIA
by: N. Kolesnyk
Published: (2016-02-01) -
Activation of Intestinal HIF2α Ameliorates Iron‐Refractory Anemia
by: Yingying Yu, et al.
Published: (2024-03-01) -
Iron-Deficiency Anemia in CKD: A Narrative Review for the Kidney Care Team
by: Debra Hain, et al.
Published: (2023-08-01) -
Safety of HIF prolyl hydroxylase inhibitors for anemia in dialysis patients: a systematic review and network meta-analysis
by: Dinghua Chen, et al.
Published: (2023-05-01)